H. Vargas

发表

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.

S. Hitchcock, A. Cheng, Yuan Cheng, 2015, Bioorganic & medicinal chemistry letters.

P11467: An Orally-Active Acetylcholinesterase Inhibitor and α2-Adrenoceptor Antagonist for Alzheimer’s Disease

J. Winslow, D. K. Rush, Craig P. Smith, 1997 .

Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.

Jennifer E. Golden, R. Bürli, Matthew R. Lee, 2011, ACS medicinal chemistry letters.

Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.

J. Winslow, H. Hartman, D. K. Rush, 1997, The Journal of pharmacology and experimental therapeutics.

Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure.

H. Vargas, A. Gorman, 1995, Life sciences.

Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1).

Jennifer E. Golden, R. Bürli, M. Lobera, 2011, ACS medicinal chemistry letters.

Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.

R. Bürli, M. Lobera, A. Saha, 2011, ACS medicinal chemistry letters.

Intracellular calcium release in N1E-115 neuroblastoma cells is mediated by the M1 muscarinic receptor subtype and is antagonized by McN-A-343

S. Wang, S. Thompson, C. Mathes, 1992, Brain Research.

A comparison of the central and peripheral antimuscarinic effects of atropine and methylatropine injected systemically and into the cerebral ventricles.

H. Brezenoff, Y. Xiao, H. Vargas, 1988, Life sciences.

Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.

U. Hacksell, B M Nilsson, H M Vargas, 1992, Journal of medicinal chemistry.

Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3.

S. A. Parent, G. Chrebet, M. Forrest, 2005, Journal of medicinal chemistry.

Synthesis and preliminary structure-activity relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor

Gordon E. Olsen, J. Winslow, D. K. Rush, 1997 .

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

A. Mutlib, D. K. Rush, G. M. Bores, 1996, The Journal of pharmacology and experimental therapeutics.

Antimuscarinic potency and functional selectivity of oxotremorine analogs at muscarinic receptor subtypes in the rat.

B. Ringdahl, H. Vargas, 1990, Life sciences.

Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.

L. Ignarro, G. Chaudhuri, H. Vargas, 1991, The Journal of pharmacology and experimental therapeutics.

Linopirdine (DuP 996) selectively enhances acetylcholine release induced by high potassium, but not electrical stimulation, in rat brain slices and guinea pig ileum

H. Vargas, Craig P. Smith, Linda R. Brougham, 1993 .

Suppression of hypertension during chronic reduction of brain acetylcholine in spontaneously hypertensive rats.

H. Brezenoff, H. Vargas, 1988, Journal of hypertension.

Elevation of cerebrospinal fluid choline levels by nicotinamide involves the enzymatic formation of N1-methylnicotinamide in brain tissue.

D. Jenden, H. Vargas, 1996, Life sciences.

Binding affinity and antimuscarinic activity of σ and phencyclidine receptor ligands

R. Pechnick, H. Vargas, 1991 .

Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog.

J. Hubbard, C. Smith, L. Zhou, 1997, The Journal of pharmacology and experimental therapeutics.

Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.

M. Fielden, D. Whittington, M. Bartberger, 2017, MedChemComm.

An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.

Xiao Mei Zheng, R. Wahl, S. Hitchcock, 2015, ACS medicinal chemistry letters.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

Physiological release of nitric oxide is dependent on the level of vascular tone.

L. Ignarro, G. Chaudhuri, H. Vargas, 1990, European journal of pharmacology.

Vascular alpha 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat.

L. Zhou, H. Vargas, 1996, European journal of pharmacology.

Role of vascular alpha-1 adrenoceptor subtypes in the pressor response to sympathetic nerve stimulation in the pithed rat.

L. Zhou, H. Vargas, A. Gorman, 1994, The Journal of pharmacology and experimental therapeutics.

Cardiovascular effects of chloroethylclonidine, an irreversible alpha 1B-adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro.

H. Hartman, L. Zhou, H. Vargas, 1993, The Journal of pharmacology and experimental therapeutics.

α2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat

J. Winslow, C. Smith, F. Camacho, 1996, Psychopharmacology.

4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.

M. Ivarsson, D. O'connor, P. Hutson, 2005, Bioorganic & medicinal chemistry letters.

Amide, urea, and carbamate analogues of the muscarinic agent [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.

U. Hacksell, H. Vargas, B. Nilsson, 1992, Journal of Medicinal Chemistry.